{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:56:31Z","timestamp":1779908191780,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070181"],"award-info":[{"award-number":["82070181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970140"],"award-info":[{"award-number":["81970140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00277-024-05682-3","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T08:02:02Z","timestamp":1709625722000},"page":"3745-3754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome\u2013positive acute lymphoblastic leukaemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Lijuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengye","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"5682_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW, M.R.C.N.C. (2007) R.I. Adult Leukaemia Working Party, Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109:3189\u20133197","journal-title":"Blood"},{"key":"5682_CR2","doi-asserted-by":"crossref","unstructured":"Burmeister T., Schwartz S., Bartram C.R., Gokbuget N., Hoelzer D., Thiel E., G.s. group (2008) Patients\u2019 age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood 112:918\u2013919","DOI":"10.1182\/blood-2008-04-149286"},{"key":"5682_CR3","doi-asserted-by":"crossref","unstructured":"Zeng Q, Xiang B, Liu Z (2021) Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Med 10:8741\u20138753","DOI":"10.1002\/cam4.4413"},{"key":"5682_CR4","doi-asserted-by":"crossref","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL trial MRC UKALLXII\/ECOG2993, blood. 113:4489\u20134496","DOI":"10.1182\/blood-2009-01-199380"},{"key":"5682_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","volume":"13","author":"B Samra","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ (2020) Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol 13:70","journal-title":"J Hematol Oncol"},{"key":"5682_CR6","doi-asserted-by":"publisher","first-page":"204062072311512","DOI":"10.1177\/20406207231151294","volume":"14","author":"FG Haddad","year":"2023","unstructured":"Haddad FG, Sawyers J, Short NJ (2023) Treatment de-escalation in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens. Ther Adv Hematol 14:20406207231151294","journal-title":"Ther Adv Hematol"},{"key":"5682_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","volume":"16","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H (2023) The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol 16:22","journal-title":"J Hematol Oncol"},{"key":"5682_CR8","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/bloodadvances.2021004813","volume":"5","author":"MJ Wieduwilt","year":"2021","unstructured":"Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Christner SM, Lewis LD, Devine S, Stone RM, Larson RA (2021) Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv 5:4691\u20134700","journal-title":"Blood Adv"},{"key":"5682_CR9","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","volume":"121","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, O\u2019Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM (2015) Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121:4158\u20134164","journal-title":"Cancer"},{"key":"5682_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Bassan R, Lion T (2019) Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol 12:39","journal-title":"J Hematol Oncol"},{"key":"5682_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbmt.2017.12.777","volume":"24","author":"J Wang","year":"2018","unstructured":"Wang J, Jiang Q, Xu LP, Zhang XH, Chen H, Qin YZ, Ruan GR, Jiang H, Jia JS, Zhao T, Liu KY, Jiang B, Huang XJ (2018) Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome-positive Acute Lymphoblastic Leukemia. Biol Blood Marrow Transpl 24:741\u2013750","journal-title":"Biol Blood Marrow Transpl"},{"key":"5682_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1756-8722-5-29","volume":"5","author":"H Chen","year":"2012","unstructured":"Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY, Han W, Zhang XH, Wang Y, Zhang YY, Qin YZ, Liu YR, Huang XJ (2012) Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. J Hematol Oncol 5:29","journal-title":"J Hematol Oncol"},{"key":"5682_CR13","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1016\/S2352-3026(22)00293-9","volume":"9","author":"YJ Chang","year":"2022","unstructured":"Chang YJ, Pei XY, Huang XJ (2022) Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. Lancet Haematol 9:e919\u2013e929","journal-title":"Lancet Haematol"},{"key":"5682_CR14","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","volume":"18","author":"H Guo","year":"2021","unstructured":"Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, Wang M, Chen H, Chen YH, Wang FR, Wei H, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ (2021) Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol 18:1172\u20131185","journal-title":"Cell Mol Immunol"},{"key":"5682_CR15","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O\u2019Brien S, Kantarjian H (2018) Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5:e618\u2013e627","journal-title":"Lancet Haematol"},{"key":"5682_CR16","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/cncr.33529","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E (2021) Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127:2648\u20132656","journal-title":"Cancer"},{"key":"5682_CR17","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","volume":"8","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Haddad FG, Short NJ, Kantarjian H (2022) Treatment of adults with Philadelphia chromosome-positive Acute Lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol 8:1340\u20131348","journal-title":"JAMA Oncol"},{"key":"5682_CR18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdw123","volume":"27","author":"JH Yoon","year":"2016","unstructured":"Yoon JH, Yhim HY, Kwak JY, Ahn JS, Yang DH, Lee JJ, Kim SJ, Kim JS, Park SJ, Choi CW, Eom HS, Park SK, Choi SY, Kim SH, Kim DW, Lee S (2016) Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol 27:1081\u20131088","journal-title":"Ann Oncol"},{"key":"5682_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, Patel K, O\u2019Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F (2016) Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128:504\u2013507","journal-title":"Blood"},{"key":"5682_CR20","first-page":"853","volume":"14","author":"YR Liu","year":"2006","unstructured":"Liu YR, Chen SS, Chang Y, Fu JY, Zhang LP, Wang H, Li LD, Zhu HH, Liu GL, Lu DP, Huang XJ (2006) [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14:853\u2013857","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"5682_CR21","first-page":"433","volume":"28","author":"YZ Qin","year":"2007","unstructured":"Qin YZ, Li JL, Zhu HH, Li LD, Chang Y, Le H, Ruan GR, Liu YR, Huang XJ, Chen SS (2007) [Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique]. Zhonghua Xue Ye Xue Za Zhi 28:433\u2013437","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"5682_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12885-016-2300-7","volume":"16","author":"QM Yao","year":"2016","unstructured":"Yao QM, Liu KY, Gale RP, Jiang B, Liu YR, Jiang Q, Jiang H, Zhang XH, Zhang MJ, Chen SS, Huang XJ, Xu LP, Ruan GR (2016) Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. BMC Cancer 16:269","journal-title":"BMC Cancer"},{"key":"5682_CR23","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O\u2019Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396\u20134407","journal-title":"Blood"},{"key":"5682_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","volume":"11","author":"L Xu","year":"2018","unstructured":"Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, Liu D, Liu Q, Liu T, Jiang M, Ren H, Song Y, Sun Z, Wang J, Wu D, Zhou D, Zou P, Liu K, Huang X (2018) The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 11:33","journal-title":"J Hematol Oncol"},{"key":"5682_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"XH Zhang","year":"2021","unstructured":"Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, Lai YR, Liu DH, Liu QF, Liu T, Ren HY, Song YP, Sun ZM, Tang XW, Wang JM, Wu DP, Xu LP, Zhang X, Zhou DB, Huang XJ (2021) The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol 14:145","journal-title":"J Hematol Oncol"},{"key":"5682_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/bjh.14778","volume":"179","author":"XD Mo","year":"2017","unstructured":"Mo XD, Lv M, Huang XJ (2017) Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. Br J Haematol 179:184\u2013197","journal-title":"Br J Haematol"},{"key":"5682_CR27","doi-asserted-by":"crossref","unstructured":"Ghobadi A, Slade M, Kantarjian HM, Alvarenga J, Aldoss I, Mohammed K, Jabbour EJ, Faramand RG, Shah BD, Locke FL, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P (2022) The role of allogeneic transplant for adult Ph\u2009+\u2009ALL in CR1 with complete molecular remission. A Retrospective Analysis, Blood","DOI":"10.1182\/blood.2022016194"},{"key":"5682_CR28","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1038\/s41375-022-01616-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Li ZY, Zhang MY, Huang XJ, Jiang Q (2022) Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. Leukemia 36:2042\u20132049","journal-title":"Leukemia"},{"key":"5682_CR29","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41375-022-01583-4","volume":"36","author":"S Yang","year":"2022","unstructured":"Yang S, Zhang XS, Gale RP, Huang XJ, Jiang Q (2022) Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase. Leukemia 36:1818\u20131824","journal-title":"Leukemia"},{"key":"5682_CR30","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P (2022) The role of allogeneic transplant for adult Ph\u2009+\u2009ALL in CR1 with complete molecular remission: a retrospective analysis. Blood 140:2101\u20132112","journal-title":"Blood"},{"key":"5682_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/j.seminhematol.2020.09.002","volume":"57","author":"L Muffly","year":"2020","unstructured":"Muffly L, Kebriaei P (2020) Philadelphia chromosome positive acute lymphoblastic leukemia in adults: therapeutic options and dilemmas in 2020. Semin Hematol 57:137\u2013141","journal-title":"Semin Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05682-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05682-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05682-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:10:28Z","timestamp":1724836228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05682-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5682"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05682-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"25 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}